Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Breakthrough” Designation Another Harmonization Opportunity, Woodcock Says

Executive Summary

An agreement with the European Medicines Agency likely would be necessary for therapies designated as breakthroughs to ensure expedited clinical program would be accepted in both jurisdictions.

You may also be interested in...



A Breakthrough Therapies Pathway In Europe? Not Likely, Regulators Say

Drug companies looking for an FDA-style breakthrough therapies pathway in Europe shouldn’t hold their breath: the current European health care reimbursement landscape, regulators say, cannot support a breakthrough pathway.

A Breakthrough Therapies Pathway In Europe? Not Likely, Regulators Say

Drug companies looking for a FDA-style Breakthrough Therapies pathway in Europe shouldn’t hold their breath: The current European health care reimbursement landscape, regulators say, cannot support a Breakthrough pathway. Europe is looking for other ways to shorten drug development times until the bigger-picture reimbursement question can be addressed. Is adaptive licensing the answer?

U.K. Early Access Scheme Now Open To All Comers, But Smaller Firms May Be Scared

MHRA will not limit the number of drugs that could be awarded the designation, but the lengthy, expensive application process could effectively limit the number of small firms that can take advantage of it.

Related Content

Topics

UsernamePublicRestriction

Register

PS054356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel